Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.79 |
| ▸ | KDM1A | O60341 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | F3 | P13726 | 1/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entinostat SCHEMBL29499905 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29838042 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29387345 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL148309 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2409897 | 0.87 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2407986 | 0.87 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL2415852 | 0.86 | HDAC1 (0.92) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2412431 | 0.86 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2412014 | 0.85 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2413749 | 0.85 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117011-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2018-05-03 | — | — | US | disclosed |
| US-20180117011-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117011-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | AR, PIK3CA, NR5A1 | HDAC1 7/4885HDAC3 16/4885HDAC2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.